TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning

Inclusion Criteria: * Patients over 18 years of age, of any race or sex, who have unresectable primary or metastatic tumors of the liver, and who are able to give informed consent. * Patients must be eligible for Y90-radioembolization treatment, have an ECOG Performance Status score of ≤ 2, with a life expectancy of ≥ 3 months, and must be non-pregnant with an acceptable contraception in premenopausal women. * At least one lesion ≥ 3.0 cm in shortest dimension * Negative pregnancy test in premenopausal women Exclusion Criteria: * Contraindications to angiography and selective visceral catheterization * Evidence of potential delivery of greater than 30 Gy absorbed dose to the lungs with a single injection. * Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels) * Infiltrative tumors * Target vessel sizes outside of TriNav device prescribed diameter range of 1.5 - 3.5 mm